Paris, France
Sanofi has taken a major step to strengthen its adult vaccines portfolio by announcing a $2.2 billion strategic deal with Dynavax Technologies, signaling an aggressive push to expand its presence in next-generation vaccine development.
Under the agreement, Sanofi will leverage Dynavax’s CpG 1018® adjuvant technology, a key immune-boosting platform already used in approved vaccines, to accelerate the development of vaccines targeting diseases with significant unmet needs in adult populations. The collaboration is expected to enhance vaccine efficacy while enabling faster and more flexible development timelines.
The deal aligns with Sanofi’s broader strategy to rebuild and scale its vaccines business beyond COVID-19, with a focus on respiratory, infectious, and emerging diseases affecting adults and older populations. By integrating Dynavax’s adjuvant expertise, Sanofi aims to strengthen immune responses across multiple vaccine candidates and expand its competitive edge in the global vaccines market.
Executives highlighted that the investment reflects growing demand for durable, high-performance adult vaccines, particularly as aging populations and evolving pathogens drive renewed focus on prevention. The partnership also underscores Sanofi’s commitment to combining internal R&D capabilities with external innovation to deliver differentiated vaccine solutions.
The Dynavax deal positions Sanofi as a stronger contender in the adult vaccines arena, intensifying competition with global peers as the race accelerates to develop more effective and scalable immunization platforms.
By
